Polyrizon shares rise after FDA meeting on PL-14 Allergy Blocker

Polyrizon Ltd. shares increased by 5.03%, crossing above the 5-day SMA, amid mixed market conditions with the Nasdaq-100 down 0.60% and the S&P 500 up 0.06%.

This rise is attributed to the successful completion of a pre-submission meeting with the FDA regarding the PL-14 Allergy Blocker, which clarifies regulatory requirements for future submissions and sets the stage for clinical trials planned for 2026. The company is well-positioned in the growing allergy market, projected to reach $210 million by 2033, enhancing its competitiveness.

The implications of this FDA meeting are significant, as it not only validates Polyrizon's development strategy but also strengthens investor confidence in its future product pipeline, potentially leading to increased market interest and stock performance.